Preclinical Therapy of Breast Cancer with a Radioiodinated Humanized Anti-EGP-1 Monoclonal Antibody: Advantage of a Residualizing Iodine Radiolabel
- 1 March 2004
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 84 (2) , 173-182
Abstract
Background. A humanized monoclonal antibody (MAb), hRS7, labeled with 131I-IMP-R4, was evaluated for the preclinical radioimmunotherapy (RAIT) of breast cancer. 131I-IMP-R4 is an improved...Keywords
This publication has 14 references indexed in Scilit:
- Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodineCritical Reviews in Oncology/Hematology, 2001
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.Journal of Clinical Oncology, 1998
- Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2)Cancer, 1997
- Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2Molecular Immunology, 1995
- The biologic window for chimeric l6 radioimmunotherapyCancer, 1994
- Processing of antibody-radioisotope conjugates after binding to the surface of tumor cellsCancer, 1994
- High dose chemotherapy with autologous stem cell support for the treatment of metastatic breast cancerCancer, 1994
- Multidisciplinary management of advanced primary and metastatic breast cancerCancer, 1994
- Specificity and properties of MAb RS7‐3G11 and the antigen defined by this pancarcinoma monoclonal antibodyInternational Journal of Cancer, 1993
- Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cellsCellular Immunology, 1991